Fatty liver is independently associated with alterations in circulating HDL2 and HDL3 subfractions

Diabetes Care

Volumn 31, Issue 2, 2008, Pages 366-368

  Kantartzis, Konstantinos ^a   Rittig, Kilian ^a   Cegan, Alexander ^a   Machann, Jürgen ^a   Schick, Fritz ^a   Balletshofer, Bernd ^a   Fritsche, Andreas ^a   Schleicher, Erwin ^a   Häring, Hans Ulrich ^a   Stefan, Norbert ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3;

ARTICLE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HUMAN; INSULIN SENSITIVITY; MALE; WAIST CIRCUMFERENCE;

ADIPONECTIN; APOLIPOPROTEINS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; MALE; REFERENCE VALUES; RISK FACTORS;

EID: 38949214066     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-1558     Document Type: Article

References (25)

1. Roden M: Mechanisms of disease: hepatic steatosis in type 2 diabetes: pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2:335-348, 2006
2. Yki-Järvinen H, Westerbacka J: The fatty liver and insulin resistance. Curr Mol Med 5:287-295, 2005
3. Tolman KG, Fonseca V, Dalpiaz A, Tan MH: Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 30:734-743, 2007
4. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42:473-480, 2005
5. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325-1330, 2006
6. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E: Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25:1045-1050, 2005
7. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212-1218, 2007
8. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546,2005
9. Ginsberg HN, Zhang Y-L, Hernandez-Ono A: Metabolic syndrome: focus on dyslipidemia. Obesity 14 (Suppl.):41S-49S, 2006
10. Toledo FG, Sniderman AD, Kelley DE: Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 29:1845-1850, 2006
11. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 46:733-749, 2003
12. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Häkkinen A, Olofson S-O, Yki-Järvinen H, Borén J: Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765, 2006
13. Navab M, Anantharamaiah GM, Reddy ST, van Lenten BJ, Ansell BJ, Fogelmann AM: Mechanisms of disease: proatherogenic HDL: an evolving field. Nat Clin Pract Endocrinol Metab 2:504-511, 2006
14. Rader DJ: Molecular regulation of HDL metabolism and function: implications fornoveltherapies. J Clin Invest116:3090-3100, 2006
15. Kontush A, Chapman MJ: Atherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3:144-153, 2006
16. Groop PH, Thomas M, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C, Taskinen MR, Viberti G: HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes. Diabetes Care 30:2706-2707, 2007
17. 3 subfractions with ischemic heart disease in men. Arterioscler Thromb Vasc Biol 17:1098-1105, 1997
18. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ: Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes: a prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 46:674-682, 2003
19. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU: High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30:1173-1178, 2007
20. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462-E468, 2005
21. Matsuda A, DeFronzo R: Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462-1470, 1999
22. 3 in human plasma. Clin Chem 2:265-270, 1989
23. Stefan N, Wahl HG, Fritsche A, Häring H, Stumvoll M: Effect of the pattern of elevated free fatty acids on insulin sensitivity and insulin secretion in healthy humans. Horm Metab Res 33:432-438, 2001
24. Bagdade JD, Subbaiah PV: Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes. J Lab Clin Med 113:235-40, 1989
25. Nguyen SD, Sok DE: Beneficial effect of oleoylated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization. Biochem J 375:275-285, 2003